钟玉案的从严处罚，绝非个案，而是其违法情节严重性招致的必然结果。作为康得新的"灵魂人物"，钟 玉策划并主导了长达七年的全链条财务造假，累计虚增利润115亿元，还涉及欺诈发行债券等多项罪 名，其行为不仅严重侵害了投资者的合法权益，更破坏了资本市场的信息披露秩序和公平交易原则。从 刑期构成来看，骗购外汇罪和背信损害上市公司利益罪是其核心量刑依据。 值得注意的是，相较于以往部分案件"重刑期轻罚金"或"重行政罚款轻刑事追责"，此次案件实现了刑期 与罚金的双重加码。这一处罚趋势的背后，是法律体系的不断完善与监管力度的持续升级。近年来， 《刑法》修正，针对欺诈发行等证券领域高发违法犯罪行为，将刑期上限由5年有期徒刑大幅提高至15 年，同时将个人罚金由"非法募集资金的1%-5%"修改为"并处罚金"，取消了5%的上限限制，为从严处 罚提供了坚实的法律依据。此外，刑法修正案明确将控股股东、实际控制人组织、指使实施欺诈发行、 信息披露造假等行为纳入刑法规制范围，从法律层面锁定了资本市场关键少数的主体责任。 12月15日晚间，康得新发布一则终审裁定公告，康得新因犯欺诈发行证券罪、骗购外汇罪被判处罚金 4.1亿元，其原董事长钟玉因犯 ...

Core Viewpoint - The company, Kangde Xin, has faced significant legal repercussions due to fraudulent activities, including securities fraud and foreign exchange fraud, resulting in substantial fines and prison sentences for key executives [1][2][3]. Group 1: Legal Proceedings - On December 11, 2025, the Jiangsu Provincial High People's Court issued a final ruling, rejecting appeals and upholding the original judgment against Kangde Xin [1]. - The first-instance judgment revealed that Kangde Xin was guilty of securities fraud and foreign exchange fraud, leading to a fine of 410 million RMB [2]. - The chairman, Zhong Yu, received a 15-year prison sentence and a fine of 20.2 million RMB for his role in the fraud [1][3]. Group 2: Details of the Fraud - The fraudulent activities spanned over seven years, involving a systematic approach to financial deception orchestrated by Zhong Yu and other executives [2]. - The total amount involved in the fraud was substantial, severely disrupting the securities market [2]. Group 3: Sentences for Other Executives - Other executives, including Xu Shu and Wang Yu, received varying prison sentences ranging from 2.5 years to 13 years, along with fines for their involvement in the fraudulent activities [3][4]. - Zhang Lixiong was sentenced to 2 years with a suspended sentence for his role in the fraud [4]. Group 4: Financial Impact on the Company - The total fine of 410 million RMB represents 3.29% of the company's most recent audited net assets, and the company has already accounted for this fine in its current profits, indicating no impact on future profits [6]. Group 5: Timeline of the Case - The case has been ongoing for over four years, with the initial indictment received in September 2021 and the final ruling made in December 2025 [7]. - The prosecution involved multiple charges against the company and its executives, highlighting the severity of the offenses committed [7].

Core Viewpoint - The court has upheld the conviction of Kangde Xin for securities fraud and foreign exchange fraud, resulting in significant penalties for both the company and its executives [1][5]. Group 1: Legal Proceedings - On December 11, 2025, Jiangsu High People's Court issued a final ruling, rejecting the appeal and maintaining the original judgment [1]. - The first-instance judgment revealed that Kangde Xin was guilty of securities fraud and foreign exchange fraud, resulting in a fine of 410 million RMB [2]. - The case has been ongoing for over four years, with the initial indictment received in September 2021 and the final ruling made in December 2025 [6]. Group 2: Penalties and Sentences - Kangde Xin was fined a total of 410 million RMB, which represents 3.29% of the company's most recent audited net assets [5]. - Chairman Zhong Yu was sentenced to 15 years in prison and fined 20.2 million RMB for multiple offenses, including securities fraud and foreign exchange fraud [3]. - Other executives, including Xu Shu and Wang Yu, received varying prison sentences and fines for their roles in the fraudulent activities [3][4]. Group 3: Nature of the Fraud - The fraudulent activities involved systematic financial deception over a period of seven years, significantly disrupting the securities market [2]. - The defendants conspired to mislead investors and authorities, leading to severe legal consequences [2][6].

Core Viewpoint - The article discusses the significant legal developments regarding Kangde Xin, including a final ruling by the Jiangsu Provincial High People's Court, which upheld the original judgment against the company and its executives for serious financial crimes, including fraud and foreign exchange violations [1][6]. Summary by Sections Legal Proceedings - On December 11, 2025, Kangde Xin received a criminal ruling from the Jiangsu Provincial High People's Court, which rejected the appeal and upheld the original verdict [1]. - The first-instance judgment indicated that Kangde Xin was guilty of fraudulently issuing securities and illegally obtaining foreign exchange, resulting in a fine of RMB 410 million [2]. Sentences for Executives - Chairman Zhong Yu was sentenced to 15 years in prison and fined RMB 20.2 million for multiple offenses, including fraud and foreign exchange violations [3]. - Other executives, including Xu Shu and Wang Yu, received varying sentences ranging from 2.5 years to 6.5 years, along with fines for their roles in the fraudulent activities [4]. Financial Impact - The total fine of RMB 410 million represents 3.29% of Kangde Xin's most recent audited net assets, and the company has already accounted for this penalty in its financial statements, indicating no impact on current or future profits [6]. Case Timeline - The case has spanned over four years, beginning with the initial indictment in September 2021, leading to various legal proceedings and the final ruling in December 2025 [7].

Core Viewpoint - The article discusses the ongoing legal actions against Kangde Xin (002450) for false statements made in financial reports, highlighting the potential for investor claims and the significant discrepancies in reported financial data from 2015 to 2018 [1][5]. Group 1: False Financial Reporting - From 2015 to 2018, Kangde Xin inflated its reported profits through fictitious sales, purchases, and expenses, resulting in total profit overstatements of CNY 2,242,745,642.37, CNY 2,943,420,778.01, CNY 3,908,205,906.90, and CNY 2,436,193,525.40, which represented 136.22%, 127.85%, 134.19%, and 711.29% of the reported profits for those years respectively [1][5]. - The reported bank balances for Kangde Xin from 2015 to 2018 were also found to be false, with actual year-end balances being zero, while reported balances were CNY 9,571,053,025.20, CNY 14,689,542,575.86, CNY 17,781,374,628.03, and CNY 14,468,363,032.12 [2][6]. Group 2: Disclosure Failures - Kangde Xin failed to timely disclose significant guarantees provided to its controlling shareholder, with guarantees amounting to CNY 1,482,700,000.00, CNY 1,463,050,000.00, and CNY 1,463,050,000.00 for the years 2016 to 2018 [3][7]. - The company did not accurately disclose the use of raised funds in its annual reports, leading to further legal implications for the firm [4][8]. Group 3: Legal Proceedings - The Shanghai Jiucheng Law Firm, represented by lawyer Xu Feng, is actively pursuing claims on behalf of investors affected by Kangde Xin's false statements, with ongoing efforts to file additional cases [1][5]. - Investors who purchased Kangde Xin shares between March 22, 2013, and January 23, 2019, and sold or held them after that date are still eligible to file claims [4][8].

Core Viewpoint - China Chemical is involved in a lawsuit related to the financial fraud case of Kangde Xin, with potential claims amounting to 4.139 billion yuan from investors due to false statements [1][4][5]. Group 1: Lawsuit Details - China Chemical's subsidiary, Ningbo Engineering Co., received a lawsuit notification regarding claims against Kangde Xin for investment losses due to false statements [1][4]. - The plaintiffs are seeking compensation for investment losses, including a total claim of 4.139 billion yuan [1][4]. - China Chemical has stated that its subsidiary was not aware of any financial fraud by Kangde Xin and does not expect the lawsuit to materially impact its profits [1][4]. Group 2: Financial Performance - In the first three quarters of 2025, China Chemical reported a revenue of 136.3 billion yuan, achieving 69.9% of its annual target [3][9]. - To meet its 2025 revenue goal of 195 billion yuan, the company needs to generate 58.7 billion yuan in the fourth quarter, representing a 13.17% increase from the previous year [3][9]. - The company has experienced stagnant revenue growth in recent years, with a reported revenue of 186.613 billion yuan in 2024, a 4.14% increase year-on-year [7][8]. Group 3: Future Outlook - China Chemical plans to achieve a new contract signing target of 370 billion yuan and a revenue target of 195 billion yuan by 2025 [2][8]. - The company has successfully completed a nylon new materials project, which is expected to enhance production efficiency and market competitiveness [10]. - The chairman of China Chemical has expressed a commitment to significantly improve the company's quality and performance over the next five years [10].

当中介机构积极履职从个案变成常态，把职业操守从倡议变成刚性要求，才能不断提升市场透明度 和运行质量，有力促进资本市场行稳致远。 (责任编辑：关婧) 监管态势发生根本变化。新证券法实施后，"零容忍"成为资本市场的执法逻辑。中介机构被置于与 上市公司同等重要的监管地位。违法成本急剧提高，市场禁入、巨额罚款成为现实，失职必问责成为明 确的制度要求。 典型案件形成强烈震慑。康美药业、康得新等案件中的高强度处罚，使得以前怕得罪客户，现在怕 违反法律正在成为一线会计师真实的职业心理。行业自律持续强化。财政部、行业协会连续推动会计师 事务所综合评价体系建设等措施，提升了审计质量的"水平线"，压缩了不规范执业的空间。市场机制倒 逼质量上升。注册制改革下，信息披露成为核心要求，非标意见与退市风险紧密关联，会计师签字就要 担责。当市场机制反向约束审计质量，倒逼会计师更谨慎、更专业、更独立。 风气之变，是监管之变、制度之变，也是行业自我纠偏的结果。下一步，继续压实中介机构"看门 人"职责，还需要多方协同发力。 一是强化审计独立性。推动审计委员会主导聘任、审计轮换制度常态化，减少上市公司实控人的干 扰，让会计师敢于说"不"。二是提升 ...

Core Viewpoint - China Chemical announced that its subsidiary, Saiding Ningbo, has received a "Notice of Response" regarding a lawsuit filed by investors, including Hu Juling, against Kangde Xin for securities false statement liability. The plaintiffs are seeking compensation of 4.139 billion yuan for investment losses, with additional claims for announcement fees of 3 million yuan and litigation costs [1] Summary by Relevant Sections - **Lawsuit Details** - The lawsuit involves claims against Kangde Xin for a total of 4.139 billion yuan in compensation for investment losses [1] - The plaintiffs also request that other defendants bear joint liability and cover additional costs of 3 million yuan for announcement fees and litigation expenses [1] - **Company's Position** - As of the announcement date, the lawsuit has not yet gone to court [1] - Preliminary verification indicates that Saiding Ningbo was not involved in any financial fraud and is not a primary responsible party [1] - The expected impact on the company's profits is deemed negligible [1]

Core Points - Beijing Bank has received a lawsuit notification from Suzhou Intermediate People's Court, being named as a defendant in the Kangde Xin Securities false statement case [1] - The case number is (2024) Su 05 Min Chu 1473, and the court hearing has not yet commenced [1] Litigation Details - The plaintiffs are investors in Kangde Xin, represented by Hu Juling and others [1] - A total of 40 defendants are involved, with Beijing Bank and its Xidan branch being the 29th and 30th defendants respectively [1] - The main defendants include Kangde Xin and its related parties, as well as responsible personnel [1] Compensation Claims - The plaintiffs are seeking compensation for investment losses amounting to 4.139 billion yuan, which includes investment differences, stamp duty, and commissions [1] - Additional costs of 3 million yuan are also being claimed [1] - The plaintiffs request that all defendants, excluding Kangde Xin, bear joint liability [1] Impact Assessment - The bank asserts that it is not the primary responsible party in this case [1] - Preliminary assessments indicate that the lawsuit will not have a substantial impact on the bank's normal operations and profits [1] - The bank will continue to monitor the situation and disclose updates in a timely manner [1]

Core Viewpoint - The importance of listed companies in stabilizing the capital market and promoting sustainable development is increasingly recognized, especially in the current environment where market sentiment is volatile. High-quality companies that focus on core operations and deliver excellent performance are essential to restore investor confidence and stabilize market expectations [1]. Group 1: Market Valuation and Investment Opportunities - A-share valuations are currently at a low level, indicating potential for recovery and highlighting long-term investment value [2][3]. - The medical industry is expected to grow significantly due to China's large population and increasing healthcare demands, driven by the "Healthy China" strategy [2]. - The market is experiencing a divergence where funds are increasingly concentrated on high-quality companies, reflecting a shift towards value investing [4][5]. Group 2: Company Actions and Strategies - Companies like Aier Eye Hospital are committed to aligning interests with investors and enhancing performance, achieving a market value of approximately 80 billion yuan, which is 12 times its initial listing value [6]. - Dabeinong is balancing short-term and long-term goals through employee stock ownership plans to ensure sustainable growth [6]. - Guolinda aims for stable revenue growth and successful cloud transformation while focusing on shareholder returns [7]. Group 3: Economic Environment and Future Outlook - Positive fiscal policies are anticipated in the second half of the year, which may improve the macroeconomic environment and boost investor confidence [3]. - The A-share market is expected to gradually return to value investing as macro policies adjust and market sentiment stabilizes [2][3]. - The inclusion of A-shares in the MSCI index is seen as a beneficial factor, indicating a potential shift in market investment styles towards high-quality growth companies [4].